Phase 3 Head and Neck Cancer Trial, Recruiting NCT04437329 Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT04437329
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a specific type of nasopharyngeal carcinoma (a cancer of the upper throat area behind the nose), confirmed by tissue testing, classified as WHO Type II or III (non-keratinizing)
  • People whose cancer has been staged as Stage III or IVa, with specific stage combinations as defined by medical staging guidelines (confirm with trial site)
  • People whose cancer has not spread to distant parts of the body
  • People aged between 18 and 65 years old
  • People whose blood cell counts meet required levels — including white blood cells, platelets, and haemoglobin — as confirmed by blood tests
  • People whose liver is functioning within acceptable ranges, as confirmed by blood tests
  • People whose kidneys are functioning within acceptable ranges, as confirmed by blood or urine tests
  • People who are considered well enough to carry out daily activities, as measured by a standard health performance scale (score above 70 out of 100)
  • People who have given their written agreement to participate in the trial

Who may not be able to join:

  • People whose tissue testing confirms a different type of nasopharyngeal carcinoma, classified as WHO Type I (keratinizing)
  • People younger than 18 or older than 65 years of age
  • People whose treatment is intended only to manage symptoms rather than to treat the cancer directly
  • People who have had another type of cancer in the past, with the exception of certain treated skin cancers or early-stage cervical cancer
  • People who have previously received radiotherapy, chemotherapy, or surgery (other than for diagnostic purposes) to the affected area
  • People who are pregnant or currently breastfeeding
  • People living with serious ongoing health conditions that could create unacceptable risks or make it difficult to follow the trial requirements — such as unstable heart disease, severe breathing difficulties requiring hospital admission, active hepatitis, or significant mental health conditions

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jinquan Liu, M.D, Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Phone: 0086-137-1086-6485

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
1 August 2020
Est. completion
30 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progress-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov